54 research outputs found
A mock circulation loop to test extracorporeal CO2 elimination setups
Background: Extracorporeal carbon dioxide removal (ECCO2R) is a promising yet
limited researched therapy for hypercapnic respiratory failure in acute respiratory
distress syndrome and exacerbated chronic obstructive pulmonary disease. Herein,
we describe a new mock circuit that enables experimental ECCO2R research without
animal models. In a second step, we use this model to investigate three experimental
scenarios of ECCO2R: (I) the influence of hemoglobin concentration on CO2 removal. (II)
a potentially portable ECCO2R that uses air instead of oxygen, (III) a low-flow ECCO2R
that achieves effective CO2 clearance by recirculation and acidification of the limited
blood volume of a small dual lumen cannula (such as a dialysis catheter).
Results: With the presented ECCO2R mock, CO2 removal rates comparable to previous
studies were obtained. The mock works with either fresh porcine blood or diluted
expired human packed red blood cells. However, fresh porcine blood was preferred
because of better handling and availability. In the second step of this work, hemoglobin
concentration was identified as an important factor for CO2 removal. In the second
scenario, an air-driven ECCO2R setup showed only a slightly lower CO2 wash-out than the
same setup with pure oxygen as sweep gas. In the last scenario, the low-flow ECCO2R,
the blood flow at the test membrane lung was successfully raised with a recirculation
channel without the need to increase cannula flow. Low recirculation ratios resulted in
increased efficiency, while high recirculation ratios caused slightly reduced CO2 removal
rates. Acidification of the CO2 depleted blood in the recirculation channel caused an
increase in CO2 removal rate.
Conclusions: We demonstrate a simple and cost effective, yet powerful, “in-vitro”
ECCO2R model that can be used as an alternative to animal experiments for many
research scenarios. Moreover, in our approach parameters such as hemoglobin level can
be modified more easily than in animal models
A Novel Mock Circuit to Test Full-Flow Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation (ECMO) has become an important therapeutic
approach in the COVID-19 pandemic. The development and research in this field strongly relies on
animal models; however, efforts are being made to find alternatives. In this work, we present a new
mock circuit for ECMO that allows measurements of the oxygen transfer rate of a membrane lung at
full ECMO blood flow. The mock utilizes a large reservoir of heparinized porcine blood to measure the
oxygen transfer rate of the membrane lung in a single passage. The oxygen transfer rate is calculated
from blood flow, hemoglobin value, venous saturation, and post-membrane arterial oxygen pressure.
Before the next measuring sequence, the blood is regenerated to a venous condition with a sweep
gas of nitrogen and carbon dioxide. The presented mock was applied to investigate the effect of a
recirculation loop on the oxygen transfer rate of an ECMO setup. The recirculation loop caused a
significant increase in post-membrane arterial oxygen pressure (paO2
). The effect was strongest for
the highest recirculation flow. This was attributed to a smaller boundary layer on gas fibers due to
the increased blood velocity. However, the increase in paO2 did not translate to significant increases
in the oxygen transfer rate because of the minor significance of physically dissolved oxygen for gas
transfer. In conclusion, our results regarding a new ECMO mock setup demonstrate that recirculation
loops can improve ECMO performance, but not enough to be clinically relevant
Comparison of Circular and Parallel-Plated Membrane Lungs for Extracorporeal Carbon Dioxide Elimination
Extracorporeal carbon dioxide removal (ECCO2R) is an important technique to treat critical lung diseases such as exacerbated chronic obstructive pulmonary disease (COPD) and mild or
moderate acute respiratory distress syndrome (ARDS). This study applies our previously presented
ECCO2R mock circuit to compare the CO2 removal capacity of circular versus parallel-plated membrane lungs at different sweep gas flow rates (0.5, 2, 4, 6 L/min) and blood flow rates (0.3 L/min,
0.9 L/min). For both designs, two low-flow polypropylene membrane lungs (Medos Hilte 1000,
Quadrox-i Neonatal) and two mid-flow polymethylpentene membrane lungs (Novalung Minilung,
Quadrox-iD Pediatric) were compared. While the parallel-plated Quadrox-iD Pediatric achieved the
overall highest CO2 removal rates under medium and high sweep gas flow rates, the two circular
membrane lungs performed relatively better at the lowest gas flow rate of 0.5 L/min. The low-flow
Hilite 1000, although overall better than the Quadrox i-Neonatal, had the most significant advantage
at a gas flow of 0.5 L/min. Moreover, the circular Minilung, despite being significantly less efficient
than the Quadrox-iD Pediatric at medium and high sweep gas flow rates, did not show a significantly
worse CO2 removal rate at a gas flow of 0.5 L/min but rather a slight advantage. We suggest that
circular membrane lungs have an advantage at low sweep gas flow rates due to reduced shunting as
a result of their fiber orientation. Efficiency for such low gas flow scenarios might be relevant for
possible future portable ECCO2R devices
NASA SpaceCube Next-Generation Artificial-Intelligence Computing for STP-H9-SCENIC on ISS
Recently, Artificial Intelligence (AI) and Machine Learning (ML) capabilities have seen an exponential increase in interest from academia and industry that can be a disruptive, transformative development for future missions. Specifically, AI/ML concepts for edge computing can be integrated into future missions for autonomous operation, constellation missions, and onboard data analysis. However, using commercial AI software frameworks onboard spacecraft is challenging because traditional radiation-hardened processors and common spacecraft processors cannot provide the necessary onboard processing capability to effectively deploy complex AI models. Advantageously, embedded AI microchips being developed for the mobile market demonstrate remarkable capability and follow similar size, weight, and power constraints that could be imposed on a space-based system. Unfortunately, many of these devices have not been qualified for use in space. Therefore, Space Test Program - Houston 9 - SpaceCube Edge-Node Intelligent Collaboration (STP-H9-SCENIC) will demonstrate inflight, cutting-edge AI applications on multiple space-based devices for next-generation onboard intelligence. SCENIC will characterize several embedded AI devices in a relevant space environment and will provide NASA and DoD with flight heritage data and lessons learned for developers seeking to enable AI/ML on future missions. Finally, SCENIC also includes new CubeSat form-factor GPS and SDR cards for guidance and navigation
DU Undergraduate Showcase: Research, Scholarship, and Creative Works: Abstracts
Abstracts from the DU Undergraduate Showcase
Genetic diversity fuels gene discovery for tobacco and alcohol use
Tobacco and alcohol use are heritable behaviours associated with 15% and 5.3% of worldwide deaths, respectively, due largely to broad increased risk for disease and injury(1-4). These substances are used across the globe, yet genome-wide association studies have focused largely on individuals of European ancestries(5). Here we leveraged global genetic diversity across 3.4 million individuals from four major clines of global ancestry (approximately 21% non-European) to power the discovery and fine-mapping of genomic loci associated with tobacco and alcohol use, to inform function of these loci via ancestry-aware transcriptome-wide association studies, and to evaluate the genetic architecture and predictive power of polygenic risk within and across populations. We found that increases in sample size and genetic diversity improved locus identification and fine-mapping resolution, and that a large majority of the 3,823 associated variants (from 2,143 loci) showed consistent effect sizes across ancestry dimensions. However, polygenic risk scores developed in one ancestry performed poorly in others, highlighting the continued need to increase sample sizes of diverse ancestries to realize any potential benefit of polygenic prediction.Peer reviewe
Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial
Background
Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population.
Methods
AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921.
Findings
Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months.
Interpretation
Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts
- …